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D 
EVELOPMENTAL growth, the remodeling and regen- 
eration of  adult tissues as well as solid tumor growth, 
can only occur accompanied by blood vessel forma- 
tion. Angioblasts and hemopoietic precursor cells differentiate 
from the mesoderm and form the blood islands of  the yolk sac 
and the primary vascular system of the embryo (vasculogen- 
esis). The formation of the rest of the vascular tree is thought 
to occur as a result of  vascular sprouting from  pre-existing ves- 
sels, a process called angiogenesis (9). 
Endothelial cells can give rise to several types of function- 
ally and morphologically distinct vessels. Upon angiogenic 
stimuli, endothelial ceils can re-enter the cell cycle, degrade 
the underlying basement membrane and migrate, forming 
capillary sprouts that projectinto theperivascular stroma, and 
again withdraw from the cell cycle and subsequently differen- 
tiate to form new vessels that are functionally  adapted to their 
tissue environment. Thus, angiogenesis, concurrent with tis- 
sue development  and regeneration depends on the tightly  con- 
trolled processes of endothelial cell proliferation, migration, 
differentiation, and survival. On the other hand, dysfunction 
of the endothelial cell regulatory system is a key feature of 
many diseases. Most importantly, tumor growth and metasta- 
sis have been shown to be angiogenesis dependent (9). 
Key signals regulating cell growth and differentiation are 
mediated by polypeptide growth factors and their transmem- 
brane receptors, many of which are tyrosine kinases. Several 
families of  receptor tyrosine kinases have been characterized 
(46). The main currently known growth factors and receptors 
transducing angiogenic stimuli are schematically shown in 
Fig.  1. Some of them, such as the receptors for fibroblast 
growth factors (FGFR),  1 platelet-derived growth factor-BB 
(PDGFRB), transforming growth factor-ol (epidermal growth 
factor receptor, EGFR), and hepatocyte growth factor (Met 
oncoprotein) are widely expressed in many tissues and cell 
types, whereas others are strictly endothelial cell specific 
(46). FGFs (for a review see reference 1) have been shown to 
be mitogenic and chemotactic for cultured endothelial cells. 
FGFs also stimulate the production of proteases such as col- 
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lagenases and plasminogen activators and induce tube forma- 
tion by endothelial cells. Cultured endothelial cells express 
FGF receptor-1 but no significant  levels of  other high-affinity 
FGF receptors. Curiously, in situ hybridization  analyses  show 
very little or no FGF receptor expression in endothelia of 
mouse embryos or human melanomas (16, 48). Thus, at least 
part of  the angiogenic effects of  FGFs in vivo may be mediated 
indirectly. 
Vascular Endothelial Growth Factor Is a 
Major Endothelial Cell-specific Angiogenesis and 
Permeability Factor 
Striking new evidence shows that there are endothelial cell 
specific growth factors and receptors that may be primarily 
responsible for the stimulation of endothelial cell growth, 
differentiation, and differentiated functions. The best studied 
of these is vascular endothelial growth factor (VEGF),  a 
member of the PDGF family. VEGF is a dimeric glycopro- 
tein of 23-kD subunits, mitogenic for endothelial cells and 
able to induce vessel permeability (alternative name vascular 
permeability factor; see references 7, 28).  Other effects of 
VEGF include the mobilization of intracellular Ca  2÷,  the 
induction of plasminogen activator, urokinase receptor (22), 
and plasminogen activator inhibitor-1  synthesis, stimulation 
of bexose transport in endothelial cells, and promotion of 
monocyte migration in vitro. Four VEGF isoforms encoded 
by distinct mRNA splicing variants appear to be equally 
capable of stimulating mitogenesis of endothelial cells, but 
have different affinities for cell surface beparan sulfate pro- 
teoglycans (HSPGs) (see reference 28). Soluble non-heparin- 
binding and beparin-binding forms have been also described 
for the related placenta growth factor (PIGF) (23,  33). 
The pattern of VEGF expression suggests its involvement 
in the development and maintenance of the normal vascu- 
lar system and in tumor angiogenesis (2, 27, 44). During mu- 
rine development, the entire 7.5-d postcoitum endoderm ex- 
presses VEGF and the ventricular neuroectoderm produces 
VEGF  at  the  capillary  ingrowth  stage  (3).  In  addition, 
epithelial cells next to fenestrated endothelia in adult mice 
show persistent VEGF expression, suggesting a role in the 
maintenance of this specific endothelial phenotype and func- 
tion (3). 
Characterization  of VEGF Receptors 
Two high affinity receptors  for VEGF have been charac- 
terized, VEGFR-1/FIt-1  (fins-like tyrosine kinase-1) (4, 43) 
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receptor/fetal liver kinase-1) (25, 27, 29, 45). The expression 
of VEGFRs occurs mainly in vascular endothelial cells al- 
though some may also be present on certain hematopoietic 
cells, such as monocytes, and in melanoma cell lines. Only 
endothelial cells have been  reported to proliferate in re- 
sponse to VEGF and endothelial cells from different sources 
show different responses. 
VEGFR-1  and VEGFR-2 bind VEGF with high affinity 
(Kd  1-20  and  75-770  pM,  respectively)  (4,  27,  45,  47). 
VEGFR-2-mediated signals cause striking changes in the 
morphology, actin reorganization and membrane ruffling of 
porcine aortic endothelial cells overexpressing this receptor 
(47). In these cells, VEGFR-2 also mediated ligand-induced 
chemotaxis and mitogenicity,  whereas VEGFR-l-transfected 
cells  lacked  mitogenic  responses  to  VEGF.  In  contrast, 
VEGF had a strong growth stimulatory effect on rat sinusoi- 
dal endothelial cells expressing endogenous VEGFRs (47). 
There is also evidence that the two forms of PIGF bind to 
VEGFR-1  (Ko about 200 pM)  but not to VEGFR-2.  Al- 
though PIGF is not a major mitogen for most endothelial 
cells, it potentiates the mitogenic activity of low concentra- 
tions of VEGF,  whereas  at higher VEGF concentrations 
PIGF had no effect (33). Heterodimerisation between VEGF 
and PIGF polypeptides has not yet been reported. 
In in situ hybridization studies, mouse VEGFR-2 mRNA 
expression was found in yolk sac and intraembryonic meso- 
derm (E7.5),  from which the endothelium is derived, and 
later in presumptive angioblasts, endocardium and large and 
small vessel endothelium (E12.5) (39). Abundant VEGFR-2 
mRNA in proliferating endothelial cells of vascular sprouts 
and branching  vessels  of embryonic and early postnatal 
brain and decreased expression in adult brain suggested that 
VEGFR-2 is a major regulator of vasculogenesis and angio- 
genesis (27).  VEGFR-1 expression was similarly associated 
with early vascular development in mouse embryos and with 
neovascularisation in hefting skin wounds (36).  However, 
high levels  of VEGFR-1  expression were also detected in 
adult organs,  suggesting that VEGFR-1  has a  function in 
quiescent endothelium of mature vessels not related to cell 
growth. The avian homologue of VEGFR-2 was observed in 
the mesoderm from the onset of gastrulation, whereas the 
VEGFR-1  homologue was first found in cells coexpressing 
endothelial markers (8).  In human fetal tissues VEGFR-1 
and VEGFR-2 showed overlapping, but slightly different ex- 
pression patterns (15). In in vitro quail epiblast cultures FGF, 
which is required for vasculogenic differentiation of these 
cells, upregulated VEGFR-2 expression (8). 
Targeted homozygous null mutations of VEGFRs indicate 
that VEGFR-2 is required for the formation of blood islands 
and  later  blood  vessels  and  for  hematopoiesis  whereas 
VEGFR-1 plays an essential role in endothelial organization 
during vascular development. Interestingly, the block in he- 
matopoiesis occurred at an early stage of differentiation in 
VEGFR-2 -/- embryos, whereas differentiation of endothe- 
lial cells proceeded as shown by the expression of early vas- 
culogenesis markers,  e.g.  VEGFR-1,  Flt4  and  TeL  Tie, 
which marks relatively later stages of endothelial cell devel- 
opment was not expressed, indicating the absence of more 
mature  endothelial cells  (personal  communications from 
Drs. G. H. Fong, F. Shalaby, and J. Rossant). These data sug- 
gest that VEGF and its receptors act in a paracrine and co- 
operative  manner  to  regulate  the  differentiation of  en- 
dothelial cells and neovascularization of tissues. 
Fit4, a VEGFR Related Receptor of the 
Lymphatic Endothelium 
Flt4 is a receptor tyrosine kinase closely related in structure 
to the products of the VEGFR-1  and VEGFR-2 genes (10, 
32).  However,  the  mature  form of Fit4  differs from the 
VEGFRs in that it is proteolytically cleaved in the extracellu- 
lax domain into two disulfide-linked polypeptides (30, 31). 
VEGF did not show specific binding to Flt4 or induce its au- 
tophosphorylation (31) and our recent results show that Flt4 
transmits signals for a novel growth factor (Joukov, V., and 
K. Alitalo, unpublished data). 
FLT4 gene expression appears to be more restricted than 
the expression of VEGFR-1  or VEGFR-2 (14, 15). The ex- 
pression of  Fit4 first becomes detectable by in situ hybridiza- 
tion in angioblasts of head mesenchyme and veins of the em- 
bryo.  During  later  stages  of development,  Fit4  mRNA 
becomes restricted to developing lymphatic vessels.  Only 
lymphatic endothelia and some high endothelial venules ex- 
press Fit4 mRNA in adult human tissues. The results support 
the theory of the venous origin of lymphatic vessels (14). 
Receptor ~rosine Kinases Tie and Tek 
Tie (tyrosine kinase with immunoglobulin and epidermal 
growth factor homology domains) and Tek (tunica interna 
endothelial cell  kinase)  comprise  another  family of en- 
dothelial cell specific receptor tyrosine kinases (5,  13, 24, 
34, 40, 41, 50). Tie cDNA was originally cloned from human 
megakaryoblastic leukemia cell lines. In vivo, its expression 
is restricted to endothelial cells and certain hematopoietic 
cells, including hematopoietic stem cells (13, 20, 21, 34, our 
unpublished data). 
During embryonic development the Tie and Tek receptors 
are uniformly expressed in endothelial cells of  blood vessels. 
Tek mRNA signals appear between days 7.5 and 8.0. In addi- 
tion to the mesoderm cell layer of the amnion, Tek marks 
vascular endothelial cells  and also  their precursors,  yon 
W'dlebrandt  factor-negative angioblasts (5). Tie is first ex- 
pressed on embryonic day 8.5  in angioblasts of the head 
mesenchyme,  in  the  splanchnopleure,  dorsal  aorta,  and 
viteUine veins.  The migrating endothelial cells in the de- 
veloping heart are also positive for Tie, as is the allantoic 
membrane (21). In adult mice the expression of Tie mRNA 
persists in vessels of  the lung whereas in the brain, heart, and 
liver it appears to decrease (21).  However,  newly formed 
capillaries in hormone-induced, maturating ovarian follicles 
and in the granulation tissue of skin wounds show somewhat 
enhanced Tie expression in the adult mouse (20). 
The Tie and Tek receptors are required for endothelial cell 
function as disruption of the corresponding gene loci by tar- 
geted mutagenesis was fatal. Tek-deficient mouse embryos 
died very early, soon after the gene should have been ex- 
pressed. The number of endothelial cells was dramatically 
decreased, the heart was underdeveloped and severe hemor- 
rhaging was detected (6). Tie-deficient embryos survived af- 
ter the time point where Tie expression normally begins, but 
died of  hemorrhage later (Sato, T., M. Puri, and J. Partanen, 
personal communication). Further studies should clarify the 
specific functions of Tie and TeL identify their ligand(s) and 
characterize the signal(s)  mediated by these receptors. 
The Journal of Cell Biology, Volume 129,  1995  896 Figure /.  Major endothelial cell receptor  tyrosine kinases and 
growth factors involved in vasculogenesis and angiogenesis. The 
structures of  the receptors are shown  schematically,  and their major 
protein  domains  have been  indicated (IGH, immunoglobulin 
homology domain; EGFH,  epidermal growth factor homology do- 
main; FNIII, fibronectin type HI homology domain; TM, trans- 
membrane domain; JM, juxtamembrane domain; TK/ and TK2, 
tyrosine kinase catalytic domains; K/, kinase insert; CT, carboxyl 
terminal tail;  Cys, cysteine-rich domains). Only ligands and re- 
ceptors with proven angiogenic  activity have been included, ot and 
/3 mark the proteolytically cleaved, disulfide-linked  subunlts of the 
Met receptor. A detail not shown  in the figure is that the Fit4 recep- 
tor is also proteolytically processed, unlike the VEGF receptors. 
Other names and abbreviations appear in the text. 
Endothelial Growth Factors and Receptors 
in Tumor Angiogenesis 
Angiogenesis has been proposed to be a rate limiting factor 
for tumor growth, playing an important role in metastasis 
(see reference 9). In several tumors, increased vasculariza- 
tion has been directly correlated with a poor prognosis. Con- 
sistent with this, highly malignant gliomas showed higher 
VEGF expression than tumors of  lower malignancy (12). Be- 
sides blood flow into the tumor, entry of tumor cells into the 
blood stream and subsequent metastasis may be facilitated 
by enhanced vascular permeability and fibrin deposition in- 
duced by VEGE 
VEGF expression in cultured cells has been shown to be 
elevated by hypoxia (44), apparently due to bypoxia-respon- 
sive elements regulated by a putative heine iron-containing 
sensor system similar to the one regulating erythropoietin 
expression (11). This provides a plausible mechanism for in- 
duction of tumor angiogenesis in the hypoxic areas of solid 
tumors. In support of  this hypothesis, elevated VEGF mRNA 
levels were detected in non-mitotic palisading cells of glio- 
blastoma surrounding necrotic areas (38, 44). Growth fac- 
tors produced by tumor cells as well as mutations in the tu- 
mor suppressor genes may also induce VEGF secretion (18, 
35).  Growth of several solid tumors in nude mice was in- 
hibited  in  vivo by treatment with monoclonal antibodies 
specific for VEGF (19). 
Significantly elevated levels  of the  Tie,  VEGFR-1  and 
VEGFR-2 mRNAs, but no Flt4 mRNA, have been observed 
in vascular endothelial cells of malignant glioblastoma. In 
comparison, there was little or no expression in endothelia 
of normal brain vasculature (12, 37).  Enhanced expression 
of the Tie receptor mRNA was also observed in the vascula- 
ture of metastatic melanomas (16). 
Inhibition of tumor angiogenesis may become effective 
therapy in several types of tumors. Of key importance for 
this kind of therapy is a clear understanding of the processes 
and regulatory mechanisms involved in blood vessel forma- 
tion. For example, it may become possible to inhibit the in- 
duction of VEGF expression by hypoxia, once the specific 
signal transduction mechanisms have been elucidated. Sev- 
eral  kinds of potential angiogenesis inhibitors have been 
reported (9). Extracellular domains of certain growth factor 
receptors have been detected in conditioned media of cul- 
tured cells and in haman blood, and they form the basis for 
competitive inhibition of  ligand binding and activation of  cell 
surface signal transducing receptors. Alternative splicing of 
VEGFR-1  transcripts  generates a  truncated soluble high- 
affinity receptor, which can inhibit VEGF-induced mitogen- 
esis of cultured endothelial cells (17). So-called dominant 
negative forms of growth factor receptors, engineered by in 
vitro mutagenesis (46)  provide a  potential tool  for anti- 
angiogenesis gene therapy. A dominant negative Tek recep- 
tor in transgenic mice produced similar phenotypic effects as 
the Tek gene knockout, e.g., dramatic hemorrhaging and de- 
creased overall number of endothelial cells (6).  Moreover, 
glioblastoma growth in nude mice was inhibited by retro- 
virus-mediated expression of  a dominant negative VEGFR-2 
(26). Inhibitors of low-affinity  binding to HSPGs or specific 
tyrosine kinase inhibitors may also have therapeutic poten- 
tial. Finally, the promoter elements controlling endothelial- 
specific expression may be useful in targeting human gene 
therapy against angiogenesis associated with tumors or other 
disease processes  involving the vascular system in,  e.g., 
blood cell trafficking, bemostasis, wound healing, and ath- 
erosclerosis. 
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